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INTRODUCTION
In spite of recent advances in diagnosis and treatment, 10
to 20% of the patients with breast cancer die within 5 yr (1).
However, 1 out of 5 patients with neglected breast cancer sur-
vived over 5 yr from the onset of symptoms even before the
1940s (2, 3). Analysis of the survival curves of women with
breast cancer suggests that there are two or more populations
among patients with breast cancer. One subgroup represents
approximately 40% of the total patients and has a relative
mortality of about 25% per year. The other subgroup repre-
senting the remaining 60% has a relative mortality rate of
about 2.5% per year (4). The relative mortality of 2.5% per
year represents a relative mortality risk equivalent to that of
cigarette smoking. These extreme outcomes have been beli-
eved to be due to heterogeneous nature of breast cancer.
Understanding the carcinogenesis of breast cancer may be
the cornerstone for solving the enigma of heterogeneity. Of
the many hypothetical models for cancer evolution, the con-
ventional model (5), also called a vertical progression, is un-
likely to apply to breast carcinogenesis. Instead, a horizontal
progression model is more acceptable, in that the grade and
biological profile of ductal carcinoma in situ (DCIS) correlate
with the invasive tumor of the corresponding grade and bio-
logical profile when DCIS progresses to invasive ductal car-
cinoma (IDC). This model has gained persuasiveness by virtue
of a pioneering study using loss of heterozygosity (LOH) anal-
ysis on the continua from the normal tissue, through poten-
tial precursors of breast cancer, to invasive cancer (6). The re-
sults also supported the presumption that proliferative disease
without atypia and atypical hyperplasia could transform dire-
ctly to invasive breast cancer without passing through the
stage of carcinoma in situ. Buerger and colleagues supported
the model by examining specific chromosomal alterations in
DCIS and associated IDC by means of comparative genomic
hybridization (CGH) (7). They reported that high-grade DC-
IS was genetically different from low and intermediate-grade
DCIS, and that the evolution of high-grade DCIS might be
along a different pathway from other grades. In the case with
concurrent IDC, the genetic alterations were similar in both
invasive and noninvasive component.
In the present study, we classified the patients with IDC
into IDC de novo and IDC associated with DCIS. Then, we
subdivided IDC associated with DCIS into two groups accor-
ding to the nuclear grade of the invasive component. To deter-
mine what biological difference existed between the three
groups, known prognostic and predictive factors (8-10) were
assessed separately and the results between the groups were
compared.  For the purpose of identifying how predictive fac-
tors affected the survival of each group, we stratified the pa-
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Heterogeneity of Invasive Ductal Carcinoma: Proposal for a 
Hypothetical Classification
To investigate what heterogeneity exists in breast cancer, 228 consecutive patients
with operable invasive duetal carcinoma (IDC), not otherwise specified, were cate-
gorized on the basis of the horizontal progression model of carcinogenesis. Using
the reversed Black’s nuclear grade (RBNG) in the IDC component and the associ-
ation of ductal carcinoma in situ (DCIS), the patients were classified into pure IDC
(IDC de novo or ab initio) as Group I, non-high grade (RBNG 1 and 2) IDC with DCIS
as Group II, and high grade (RBNG 3) IDC with DCIS as Group III. The Groups clas-
sified in the present study appeared as a prognostic factor independent of known
prognostic and predictive factors in multivariate test. Group I had the worst prognosis
among the three groups and was the most non-responsive to tamoxifen. After per-
forming stratifying analyses by group, it was found that metastasis-free survival was
statistically associated with the status of hormone receptors estrogen receptor and
progesterone receptor and tamoxifen therapy only in Group II. In addition, the sta-
tus of c-erbB-2 expression had prognostic significance only within the Group III. Our
results may be used to frame an alternative hypothetical model for breast cancer
evolution and will lead us to reconsider the tailoring of the comprehensive therapeu-
tic modality used at the present time.
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tients into groups and calculated the metastasis-free survival
in each group by adjusting each predictive factor. 
This study was designed on the premise that heterogene-
ity might be derived from the diversity of the original cells
as well as from distinct subsets of genetic alterations. The re-
sults from this study will lead us to expand the concept of
breast carcinogenesis, as well as force us to reconsider the para-
digm of the comprehensive therapeutic approach to breast
cancer.
MATERIALS AND METHODS
Patient selection
256 consecutive patients diagnosed with primary operable
invasive breast carcinoma who underwent surgery at Sam-
sung Cheil Hospital of Sungkyunkwan University between
1996 and 1997 were reviewed. In order to guarantee at least 5
yr of follow-up, the end of 1997 was set as the cut-off date.
The patients were identically submitted to receive adjuvant
systemic therapy according to the contemporary therapeutic
guidelines determined by their clinical and pathological find-
ings. Any tumor that demonstrated at least 90% defining
histologic characteristics of a special-type cancer was desig-
nated as that special type. Patients who had special types (17
cases), who refused the guideline-based adjuvant systemic
therapy (3 cases), refused further resection and/or radiotherapy
for pathologically positive resection margin (2 cases), who were
diagnosed with the second metachronous breast cancer (2
cases), and who had inappropriate surgical specimens due to
neoadjuvant therapy (5 cases) were excluded from the analysis
to eliminate any confounding effect on clinical outcome.
228 IDC were reviewed retrospectively on the basis of hospi-
tal records and contact with patients or their families. Pa-
tients were observed through physical examination and radio-
logical study every 6 months for the first 2 yr after surgery,
and thereafter with biannually physical examination and an-
nual radiological study. The median follow-up of the living
patient was 62 months (range, 6 to 80). The median age of
the patients was 46 yr (range, 24 to 76). Anyone who sub-
mitted to hormonal therapy received 20 mg of tamoxifen for 5
yr or until the last follow-up. 
Pathologic examination
Pathologic information on nodal status and tumor size was
obtained from the original reports. Paraffin block was made
in 5 mm-thickness with the surgical specimen that had been
grossly suspicious of tumor. A 4  m-thick slide was prepared
from each block and was examined for the original reports.
When DCIS was suspected of focal invasion or pure IDC was
suspected of associating focal DCIS, the 5 mm-thick paraffin
block was silced in 2 mm-thickness. A slide was obtained
from every 2 mm-thick paraffin block additionally and was
examined. The association of DCIS was noted on all the pa-
thologic reports when it was associated with IDC. The tumor
size of invasive component was determined by gross measure-
ments of the surgical specimen or by the largest diameter on
the slide. The nuclear grade of the invasive component in each
tumor was assessed according to a modification of Black’s nu-
clear grade (reversed Black’s nuclear grade, RBNG, Fig. 1)
by peer-review (11). In order to minimize intra/inter-observ-
er bias, all slides were repeatedly reviewed by a single pathol-
ogist until the result was uniform.
5  m- sections of formalin-fixed, paraffin-embedded breast
cancer specimens were prepared on polysine coated slides.
Immunohistochemical staining was performed using the stre-
ptoavidin-biotin method, according to the supplier’s proto-
col (DAKO, LSAB kit, Carpinteria, CA, U.S.A.). We used
monoclonal mouse anti-(human Ig) antibodies directed agai-
nst estrogen receptors (ER) (DAKO, 1:100), progesterone re-
ceptors (PR) (DAKO, 1:50), and p53 (DO-7, DAKO, 1:100).
Immunohistochemistry for c-erbB-2 (DAKO, 1:150) was
done with polyclonal rabbit anti-(human Ig) antibodies. The
expression of ER, PR, and p53 showing more than 5% of
nuclear immunostaining was defined as positive. For c-erbB-
2, a four-tier system of scoring, as recommended by Dako cor-
poration, was used (12). Complete cytoplasmic membrane
staining (2+ or 3+ score) in more than 10% of the cells was
read as positive. Partial membrane staining (1+ score) or no
(0 score) membrane stain was read as negative. 
Patient classification
The patients whose IDC was not associated with DCIS were
classified as Group I. The patients with IDC associated with
DCIS were divided into two groups according to the RBNG
of the invasive component. IDC with RBNG 1 or 2 was arbi-
trarily defined as non-high grade IDC, and the patients with
non-high grade IDC were classified as Group II. IDC with
RBNG 3 was defined as high grade IDC, and the patients
with high grade IDC were classified as Group III. 
Clinical outcomes
In order to compare malignant capacity among three groups,
we used metastasis-free survival (MFS) as a clinical parameter.
MFS was defined as the elapsed time from surgery to distant
disease recurrence or death. The patients were censored at the
last known follow-up as being without metastasis when me-
tastasis was unknown. During the follow-up period, a patient
died of congestive heart failure and was censored.
Statistical analyses
Statistical analyses were conducted in SPSS (version 9.0).
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PR, p53, c-erbB-2, and menopausal status using the Pearson
chi-square test. Tumor size and nodal status were staged as
T0, T1, T2, T3 or N0, N1, N2, and N3 according to the 6th
edition of TNM classification. The distribution of T stage
and N stage was compared among the three groups using the
Pearson chi-square test. Cumulative MFS curve for each group
was calculated using Kaplan-Meier method and compared
among the three groups by log rank test. To identify what
variables related independently to MFS, multivariate analy-
sis was performed by Cox regression test including ER, PR,
p53, c-erbB-2, tumor size, nodal status, RBNG, and the group.
After stratifying patients by group, MFS for subgroups adjust-
ed with the status of ER, PR, p53, c-erbB-2, and tamoxifen
therapy within each group were calculated on the Kaplan-
Meier cumulative survival curve. To investigate how the pre-
dictive factors and tamoxifen therapy affected survival in each
group, the MFS for the subgroups were compared within each
group by a log rank test. Statistical significance was accepted
when the p-value was less than 0.05. 
RESULTS
Patients characteristics
84 cases (36.8%) were included in Group I. Group II and
Fig. 1. Reversed Black’s nuclear grade of invasive ductal carci-
noma (H&E stain, ×400). Tumor cells in invasive component of
ductal carcinoma, not otherwise specific, show grade 1 (A), 2( B),
and 3 (C), respectively.
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III included 74 cases (32.5%) and 70 cases (30.7%) respec-
tively (Table 1). The mean age was similar among the three
groups, whereas the proportion of premenopausal women was
largest in Group III (p=0.029). The primary surgical and ad-
juvant treatment were also similar in the three groups. Details
of patient characteristics are listed in Table 1.
Prognostic and predictive factors
Table 2 shows the distribution of the prognostic and pre-
dictive factors in the three groups, and describes the relation-
ship between the factors and groups. The distributions of T
stage and N stage were similar in 3 groups. ER, PR, and p53
were assessed in 216, 216, and 211 cases, respectively. ER
status was statistically different between the groups (p<0.001).
ER was most frequently positive in Group II (80.0%). PR
status was also statistically different between the groups (p=
0.022). PR was most frequently positive in Group II (68.6%).
The positive rate of p53 expression was significantly differ-
ent between the groups (p=0.040). Of 228 cases, 211 cases
were assessable for c-erbB-2 expression. There was no differ-
ence in the positive rate of c-erbB-2 expression between the
groups (p=0.243). 
Metastasis-free survival 
MFS analysis comparing groups is described in Table 3,
*p-value was calculated by log rank test in the Kaplan Meier cumulative
survival curve.
I 84 23 61 (72.6)
II 74 7 67 (90.5) 0.010
III 70 11 59 (84.3)
Number
p-value*
Total Events Censored (%)
Group
Table 3. Metastasis-free survival analysis comparing groups
Metastasis-free survival (months)
Survival function (p=0.010)
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Fig. 2. Metastasis-free survivals in three groups.
Group 
Group III
Group III-censored
Group I
Group I-censored
Group II
Group II-censored
*All p-values were calculated by the Pearson chi-square test, except the
mean age of the patients (
� by ANOVA). 
� The group I consists of 31 inva-
sive ductal carcinomas with non-high nuclear grade and 53 invasive duc-
tal carcinomas with high nuclear grade. MRM, modified radical mastec-
tomy; BCS, breast conservation surgery; RT, radiotherapy at the ipsilat-
eral breast and axilla; LRRT, radiotherapy at the ipsilateral breast, axilla,
and supraclavicular lymph nodes; CMF, cyclophosphamide+methotre-
xate+5-fluorouracil; FAC, 5-fluorouracil+doxorubicin+cyclophosphamide.
Group
p-value*
I II III
Charateristics 
Group 
n=228 84
� 74 70
Proportion (%) 36.8 32.5 30.7
Mean age (yr) 47.8 47.6 46.0 0.600
�
Menopausal status 0.029
Premenopause (%) 54 (64.3) 50 (67.6) 58 (82.9)
Menopause (%) 30 (35.7) 24 (32.4) 12 (17.1)
Locoregional treatment 0.559
MRM (%) 61 (72.6) 55 (74.2) 53 (75.7)
BCS+RT (%) 14 (16.7) 15 (20.3) 11 (15.7)
MRM+LRRT (%) 9 (10.7) 3 (4.1) 6 (8.6)
BCS+LRRT (%) 0 1 (1.4) 0
Chemotherapy 0.134
Not received (%) 17 (20.2) 13 (17.6) 14 (20.0)
CMF (%) 60 (71.4) 61 (82.4) 53 (75.7)
FAC (%) 7 (8.3) 0 3 (4.3)
Tamoxifen therapy 0.749
Not received (%) 22 (26.2) 20 (27.0) 22 (31.4)
Received (%) 62 (73.8) 54 (73.0) 48 (68.6)
Table 1. Patient characteristics
*All p-values were calculated by the Pearson chi-square test.
� TNM classification by AJCC (6th).
Group
p-value*
I II III
Charateristics 
Tumor size
� 0.694
T1 (%) 46 (54.8) 50 (67.5) 43 (61.4)
T2 (%) 32 (38.0) 22 (29.7) 22 (31.4)
T3 (%) 3 (3.6) 1 (1.4) 2 (2.9)
T4 (%) 3 (3.6) 1 (1.4) 3 (4.3)
Nodal Status
� 0.813
N0 (%) 45 (53.6) 40 (54.1) 43 (61.4) 
N1 (%) 18 (21.4) 20 (27.0) 15 (21.4)
N2 (%) 13 (15.5) 10 (13.5) 7 (10.0)
N3 (%) 8 (9.5) 4 (5.4) 5 (7.2)
Estrogen receptor <0.001
Positive (%) 35 (43.2) 56 (80.0) 32 (49.2)
Negative (%) 46 (56.8) 14 (20.0) 33 (50.8)
Progesterone receptor 0.022
Positive (%) 39 (48.1) 48 (68.6) 32 (49.2)
Negative (%) 42 (51.9) 22 (31.4) 33 (50.8)
P53 0.040
Positive (%) 37 (46.3) 22 (32.4) 35 (55.6)
Negative (%) 43 (53.2) 46 (67.6) 28 (44.4)
C-erbB-2 0.243
Positive (%) 45 (56.3) 41 (60.3) 44 (69.8)
Negative (%) 35 (43.7) 27 (39.7) 19 (30.2)
Table 2. Prognostic factors and predictive factors464 B.-H. Jo, Y.-K. Chun
and is depicted by the Kaplan-Meier cumulative curve (Fig.
2). Group II showed significantly favorable outcome (p=0.010)
with 90.5% of MFS rate during the follow-up period in com-
parison to 72.6% in Group I and 84.3% in Group III. In the
multivariate analysis, the independent factors associated with
MFS were Group (p=0.025), nodal status (p=0.000), tumor
size (p=0.038), and RBNG (p=0.024) whereas ER, PR, p53,
c-erbB-2, and menopausal status did not emerge as a prog-
nostic factor (Table 4). Table 5, 6 describe MFS for subgroups
within each Group adjusted with ER and PR, respectively.
Within Group II, the subgroup of patients with ER positive
showed better survival function than the subgroup with ER
negative (p=0.011) while no significant difference in survival
function existed between the subgroups in either Group I or
III. In Group II, the subgroup of patients with PR positive
showed statistically better survival function than the subgroup
with PR negative (p=0.025), while no significant difference
in survival function existed between the subgroups in either
Group I or III. In regards to the status of p53 expression, it
had no statistically significant influence upon the patient’s
survival function in any group (p=0.405, 0.243, and 0.260
in Group I, II, and III, respectively). The subgroup with c-
erbB-2 positive had worse prognosis than that with c-erbB-
2 negative in Group III (p=0.035), but not in Group I (p=
0.167) or II (p=0.180). MFS for groups adjusted with tamoxi-
fen therapy had a similar tendency to that with ER and PR.
Within Group II, the subgroup of patients who received ta-
moxifen showed significantly better survival function than
the subgroup of the patients who had not received it (p=0.018),
while no difference in survival function existed between the
two subgroups within either Group I or III (Fig. 3).
*p-value was calculated by log rank test in the Kaplan Meier cumulative
survival curve.
I 81 22 59 (72.8)
Positive 39 12 27 (69.2) 0. 460 
Negative 42 10 32 (76.2) 
II 70 7 63 (90.0)
Positive 48 2 46 (95.8) 0.025
Negative 22 5 17 (77.3)
III 65 10 55 (84.6)
Positive 32 7 25 (78.1) 0.103
Negative 33 3 28 (90.9)
Overall 216 39 177 (81.9)
Number
p-value*
Total Events Censored (%)
Group PR
Table 6. Metastasis-free survival for groups adjusted with pro-
gesterone receptor (PR)
*p-value was calculated by log rank test in the Kaplan Meier cumulative
survival curve.
I 81 22 59 (72.8)
Positive 35 11 24 (68.6) 0. 529 
Negative 46 11 35 (76.1) 
II 70 7 63 (90.0)
Positive 56 3 53 (94.6) 0.011
Negative 14 4 10 (71.4)
III 65 10 55 (84.6)
Positive 32 5 27 (84.4) 0.893
Negative 33 5 28 (84.8)
Overall 216 39 177 (81.9)
Number
p-value*
Total Events Censored (%)
Group ER
Table 5. Metastasis-free survival for groups adjusted with estro-
gen receptor (ER)
Fig. 3. Metastasis-free survival adjusted with tamoxifen treatment in the three groups.
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Survival functions in group I
Metastasis-free survival (months) Metastasis-free survival (months) Metastasis-free survival (months)
Survival functions in group II Survival functions in group III
p=0.458
p=0.018
p=0.303
Tamoxifen therapy
Received
Received-censored
Not Received
Not received-censored
Tamoxifen therapy
Received
Received-censored
Not received
Not received-censored
Tamoxifen therapy
Received
Received-censored
Not received
Not received-censored
*p-value was calculated by cox regression test. RBNG, reversed Black’s
nuclear grade; ER, estrogen receptor; PR, progesterone receptor.
Variables p-value*
Group 0.0254
Nodal status 0.0000
Tumor size 0.0389
RBNG 0.0243
ER 0.8970
PR 0.8132
p53 0.9576
c-erbB-2 0.1135
Menopaual status 0.1163
Table 4. Multivariate analysis for metastasis-free survivalHeterogeneity of Invasive Ductal Carcinoma 465
DISCUSSION
Breast cancer is well known for comprising a heterogeneous
spectrum of malignant proclivities, and its initiation and early
progression are associated with genetic abnormalities. There
has been a presumptive mechanism that makes for the het-
erogeneity of breast cancer. The mechanism is that distinct
series of genetic alterations result in heterogeneous pheno-
types of breast cancer (5, 6). According to the mechanism,
there are at least three genetically different types of breast
cancer, which are the pure IDC that dose not pass through
the stage of DCIS, non-high grade IDC associated with DCIS,
and high grade IDC associated with DCIS. When cancers
clustered by certain series of genetic alterations express iden-
tical biological characteristics including their clinical out-
come, this mechanism could be exclusively accepted. Recent-
ly a challenging mechanism has been proposed that the het-
erogeneity of breast cancer may be derived from the diversity
of the original cells for neoplastic transformation, which is
thought to exist in the terminal duct lobular unit of the hu-
man mammary gland (13, 14). The cells in the terminal duct
lobular unit basically consist of glandular and myoepithelial
cells. If all the cancer expressing certain specific cellular lin-
eage markers have the same natural history, the second hypo-
thesis must be true. In the view of diachrony, however, details
of genetic alterations in cancer change with progression in
some breast cancers. Furthermore, the genetic alterations in
a clone tend to increase substantially from DCIS to IDC (15,
16). A group of investigators found that a certain genotype
predisposes to the basal tumor subtype, resulting in poor
clinical outcome (17). Therefore, it is much more reasonable
to accept the combination of both mechanisms. 
Notwithstanding the importance of the second mechanism,
the present study has been designed on the basis of the first
mechanism because the second is still in experimental stage.
In parallel, authors have presumed that pure IDC would orig-
inate from the cell located at a place easily accessible to destroy
the barrier to stromal invasion, namely, the basement mem-
brane, from the beginning of its evolution. Previous studies
have reported that pure IDC accounted for 20 to 40% of all
diagnosed IDC, not otherwise specific (18, 19). These wide-
ranged proportions of pure IDC are thought to vary with the
proportion of microscopically undetectable DCIS associated
with IDC. Certain category of DCIS has progressed to IDC
so fast that it might have been determined to be pure IDC at
the time of diagnosis. Even with this uncertainty, one cannot
help but accept the existence of pathologically pure IDC un-
less pathologists cut paraffin-blocks thick enough to examine
all ducts or lobules and, thereafter, affirm concurrent DCIS. 
The patients in the present study were divided into 3 gro-
ups as a group of pure IDC (Group I) and two groups of IDC
with DCIS (Group II and III). There were significant differ-
ences in MFS among the groups, and Group I had the worst
prognosis, as the authors had predicted. Silverberg et al. (18)
also reported that the patients with pure IDC had worse pro-
gnosis than those with IDC with DCIS. Of the many factors
indicating prognosis at the initial treatment of breast cancer,
tumor size, nodal status, and histological grade are the prog-
nostic factors for which clinical value have been confirmed
(8, 20). Because tumor size or nodal status is a momentary
feature of diachronic change, the causal relation between the
factors and prognosis needs no further explanation other than
its terminology. In other words, there is no doubt that the
size of tumor proportionally reflects the possibility of metas-
tasis (21). A recent study revealed that the survival time after
metastasis varied with the histological grade of the primary
tumor, not the size or nodal status of the primary tumor (22).
So what determines the histological grade of breast cancer?
Should it be time, genotype, or the original cell? How can
histological grade affect the fate of patients? These are theses
that need to be demonstrated. 
The lethality of regionally treated breast cancer without
systemic therapy is directly related to nuclear grade (23). Nu-
clear grade can be assessed even in a minimal invasive carci-
noma or in a specimen taken by preoperative core-needle bio-
psy. In addition, Leong et al. (24) found that the nuclear grade
of DCIS produced significant correlation with the largest num-
ber of parameters known to be of prognostic relevance in both
concurrent IDC as well as DCIS. These are the reasons that
we have taken RBNG in the present study as the pathologic
grade of IDC instead of the modification of the Bloom and
Richardson criteria (20), which is used worldwide now.
Interobserver disagreement between low and intermediate
nuclear grade was very high in one study (25). Many studies
showed a statistically significant difference in the outcome
only between high grade and non-high (low and intermedi-
ate) grade DCIS, and this concept has been confirmed by the
study of biologic marker (26). We divided IDC with DCIS
into two groups as the IDC with non-high grade nuclear grade
(Group II) and that with high nuclear grade (Group III). In
our study, Group II showed more favorable metastasis-free
survival than Group III. 
More than a few different biologic characteristics appeared
among the three groups in the present study. There was no
comparable data derived from the studies that use the same
classification as we did, as well as that was performed with
more refined design. In addition to the retrospective analysis,
the population size of the present study is not sufficient to
provide conclusive information. Nevertheless, the present
study has yielded some intriguing results for which implica-
tions must be clarified.
First, the frequency of premenopausal women was remark-
ably higher in Group III (82.9%) compared to both Group
I (64.3%) and II (67.6%), even though the mean age was simi-
lar in all three groups.
Second, there were statistically significant differences in
MFS among the three groups in univariate analyses. In addi-
tion, the Group was a prognostic factor independent of tumor466 B.-H. Jo, Y.-K. Chun
size, nodal status, nuclear grade, and important predictive
factors in multivariate analyses. 
Third, the nuclear grade appeared as an independent prog-
nostic factor in multivariate analysis and the proportion of
the patients with high nuclear grade IDC was larger in Group
III (100%) than in Group I (63%), while Group III showed
more favorable survival function that Group I (Table 1).
Fourth, in stratifying the patients by group, MFS was ad-
justed with tamoxifen treatment and four major predictive
factors (ER, PR, p52, and c-erbB-2). Only in Group II, ER
or PR positive subgroup as well as the tamoxifen-treated sub-
group showed significantly better survival function than their
counterparts, even though neither ER nor PR status was an
independent prognostic factor in multivariate analysis for all
the patients included in the present study. While c-erbB-2
was not an independent prognostic factor in multivariate anal-
ysis, the prognostic value of c-erbB-2 expression was demon-
strated in Group III, but not in Group I or II.
Many controlled studies adjusting the subsets of nodal sta-
tus or tumor size have been tried. The prognostic significance
of c-erbB-2 overexpression has not yet been adequately vali-
dated (8). So what makes the prognostic value of c-erbB-2
statistically apparent in Group III in the present study? More
sophisticated studies are needed to solve the question. There
have been conflicting opinions on whether the ER or PR sta-
tus itself is a significant predictor of clinical outcome, or not
(8). In the present study there was a questionable tendency
of tamoxifen having had no survival benefit in Group I and
III, in addition to the fact that the subgroup that received
tamoxifen in Group I showed an even lower MFS rate than
its counter subgroup even though it had no statistical signifi-
cance (Fig. 3). When this finding is reproduced in a large scale-
controlled study, we will have to change the strategy of the
systemic therapy has been recommended for the patients with
breast cancer until now. The paradigm that breast cancer is
a heterogeneous disease should be also shifted to the new one
that breast cancer consists of at least two different diseases.
The authors have formed a hypothesis that the original cell
of the cancers in Group I would be biologically different from
that of the cancers in the remaining two groups. This is the
speculation that the authors are trying to derive from the
present study. 
Authors postulate that the pure IDC might originate from
developmentally primitive cells that can differentiate into
myoepithelial cell. The adult mammary epithelial stem cell,
multipotent progenitor, and basal (or myoepithelial) progeni-
tor can be proposed as these cells (13, 14). With genetic muta-
tions, these cells transformed to the cells that fail to differen-
tiate into more differentiated cells, the glandular cells, the
myoepithelial cells, or the alveolar cells. This might be the
reason why there is no myoepitheial cell or alveolar cell in the
invasive component of IDC. Of course, these cells are apt to
grow without constructing the basement membrane, in other
words, they grow with invading stromal tissue from the be-
ginning. Even these cells could build the basement mem-
brane, the spatial characteristic of progenitor cells allows the
cancer to grow out of the basement membrane at birth. It ser-
ves as a crack on the bombshell and acts like a bomb that ex-
plodes as soon as its bombshell breaks. As a matter of course,
it does not have enough time to develop a preneoplastic field
such as that concept of field cancerization of Slaughter et al.
(27), so the cancer never passes through DCIS. In consequen-
ce, metastasis can also occur from the early stages of cancer
under such a condition. This postulation will be very practi-
cal for breast surgeons because pure IDC would define the
real systemic category of breast cancer. Accordingly, preoper-
ative systemic therapy and lumpectomy could be the stan-
dard treatment in patients with pure IDC. Moreover, the trans-
formed stem or progenitor cells should respond to tamoxifen
different from the cells that were transformed at more differ-
entiated stage. It can be presumed that this may give rise to
resistance, or even adverse effect to tamoxifen in Group I re-
gardless of the status of ER or PR. From the viewpoint of the
development of the human mammary gland, this category
should define a small proportion of all breast cancers on ac-
count of the small population of the myoepithelial cells rel-
ative to the glandular cells in normal breast tissue. In the pre-
sent study, Group I defined 36.8% of the total cases. This is
too large a proportion in comparison with the range from
16% to 28% in the previous studies carried out with the im-
munohistochemistry using antibodies against breast basal (or
myoepithelial) cell cytokeratins (14, 28). The discrepancy
between the proportion of Group I and the proportion of the
patients with basal cytokeratin-expressing cancer in the stud-
ies is thought to stem from the fact either Group I could not
directly reflect the biologic properties of pure IDC or because
Group I was conflated with pure IDC and IDC associated
with microscopically undetected DCIS. Therefore, an appro-
priate pathological guideline to characterize pure IDC should
be created. In order to purify Group I as biologically pure
IDC, an immunochemical study using biomakers that sort
cancer cells by each developmental stage is needed. These bio-
markers are thought to be glandular or basal cytokeratins,
alpha-smooth muscle actin, and certain mammary stem cell
markers. Now the expression of the biomarkers representing
the characteristics of stem cell or of cellular lineages of the
mammary gland is under investigation in various types of
breast cancer as the next step of our project.
Expounding the hypothetical pathogenesis of cancer in
Group II or III seems to be more complex (29). We have to
take a rain check on it until we have a definitive result from
our successive studies. 
If biologically different subgroups are conflated into a gro-
up and are tailored by the same therapeutic modality, some
of them may be deprived of the chance for receiving the cor-
rect regimen, or some others may lose the golden time for
optimal systemic therapy. The limit of follow-up duration,
insufficient size of population, and uncontrolled retrospectiveHeterogeneity of Invasive Ductal Carcinoma 467
analysis are the criticizable drawbacks of the present study.
The force of mortality in the overall survival curve is similar
to virulence (the rate of appearance of distant metastasis), but
competing mortality obscures metastagenicity (the ultimate
likelihood of a tumor developing distant metastasis) when
survival serves as the end point (9). Considering this and the
fact that metastatic breast cancer is incurable, the time of dis-
tant metastasis can be more suitable as the end point of fol-
low-up than death as a point at which to compare mortalities
between subgroups in case the duration of follow-up does not
reach 10 yr. Taking the time of distant metastasis as the end
point can offset the limit of follow-up duration in this study.
In order to overcome the problem of insufficient sample size
and uncontrolled study design, we have only to apply this
hypothetical classification to some larger- scale-controlled
study already reported (30). If the results correspond to ours,
this classification can be used to test the efficacy of newly de-
veloped drugs, and to determine the fashioning of a specific
tailored therapy. Ultimately, we might have to treat the three
groups as individual disease entities, just as hematologists
define leukemia according to the cellular lineages derived
from hematopoietic stem cell.
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